ArticleAnnals of medicine and surgery (2012)2026
Nanoparticle-enhanced cytology: a 2025 breakthrough for rapid diagnosis of Erdheim-Chester disease.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erdheim-Chester disease (ECD) is an ultra-rare non-Langerhans cell histiocytosis characterized by CD68-positive, CD1a/S100-negative histiocytes, frequently associated with BRAF V600E and MAPK pathway mutations. Diagnosis remains challenging due to its nonspecific presentation, reliance on invasive biopsies, and frequent diagnostic delays of several years. Nanoparticle (NP)-enhanced cytology, including surface-enhanced Raman spectroscopy, represents a promising breakthrough in 2025, enabling single-molecule sensitivity and multiplexed biomarker detection on cytology slides. NP-based imaging agents, such as Cu-Macrin for positron emission tomography, demonstrate high specificity for macrophage-rich lesions, while NP assays improve capture of circulating tumor DNA, including BRAF V600E. When integrated with AI-driven image analysis, NP-based approaches may overcome current diagnostic barriers, enabling earlier, less invasive, and more precise identification of ECD. Standardization of NP-based diagnostic protocols and continued research are essential to validate these emerging technologies and translate them into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.